Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

WOCN Society launches campaign to raise awareness about benefits of specialized care

Patients and families who are dealing with conditions such as non-healing wounds, bedsores, bladder and bowel incontinence and ostomy-related issues contend with physical symptoms, as well as social and emotional side effects. The impact on patients and families can exact an enormous toll. The Wound Ostomy & Continence Nurses Society is launching a campaign to raise awareness about the benefits of specialized care.

31 Mar 2010

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Pisgah Labs, a drug product development company and an active pharmaceutical ingredient manufacturer (API) located in western North Carolina, has received a patent allowance in a series of patent applications. The US Patent & Trademark Office (USPTO) has notified Pisgah Labs, Inc. that a patent application related to a therapeutically significant family of pharmaceutical polymorphic compositions of imipramine pamoate has been allowed. The patent application also includes methods of manufacturing, purifying and use in pharmaceutical preparations.

26 Mar 2010

Beaumont Hospital opens women's urology center

It’s something that women don’t talk about even to their best friends or their doctors. That’s why Beaumont Hospitals has created a new Women’s Urology Center offering leading-edge treatments, innovative research and the most advanced minimally invasive procedures for women’s urological conditions such as incontinence, pelvic pain and sexual dysfunction.

25 Mar 2010

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.

25 Mar 2010

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,668,598 covering the stimulation method used in the Urgent® PC Neuromodulation System.

23 Mar 2010

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD). There were no clinically significant safety concerns noted. Preliminary results demonstrated clinically significant improvements in percent change in forced expiratory volume in one second (FEV(1)).

18 Mar 2010

Adult female stress urinary incontinence: Uroplasty launches new endoscopic injection needle

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the introduction of a newly designed endoscopic injection needle that can be used in conjunction with the system used to inject Macroplastique®. Macroplastique is a soft-tissue urethral bulking agent used to treat adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. This permanent, nonresorbable material is injected into the tissues surrounding the urethra to help improve urethral closure to enhance bladder control.

10 Mar 2010

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

New research published in today's issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive.

9 Mar 2010

Likvor receives first order for Likvor CELDA system from Aalborg Hospital, North Denmark Region

LinkMed’s portfolio company Likvor has received its first order for the Likvor CELDA™ system from a customer outside Sweden. The order comes from Aalborg Hospital which is the largest hospital in the North Denmark Region.

8 Mar 2010

Urinary catheterization of men and women: NAFC releases new consumer educational resource

The National Association For Continence (NAFC) has released a new consumer educational resource, focusing on catheterization procedures and care in the United States. The Urinary Catheterization of Men and Women pamphlet is the newest addition to NAFC's library of educational materials available to consumers seeking knowledge of management and treatment options for medical problems related to incontinence. It is also helpful as an educational supplement to nurses giving instructions to patients regarding their self-care.

4 Mar 2010

Macroplastique effective for stress urinary incontinence in women

Uroplasty, Inc. highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of The Journal of Urology(R). The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.

4 Mar 2010

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company’s Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.

2 Mar 2010

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of the SUmiT Trial of its Urgent® PC Neuromodulation System that will be published in the April 2010 print edition of THE JOURNAL OF UROLOGY® and is now available on line.

1 Mar 2010

Study: Several types of treatment can provide relief for pelvic floor disorders

Pelvic health concerns in women are common -- yet how the issues impact sexuality and childbearing is not often discussed, according to Mayo Clinic Women’s HealthSource.

18 Feb 2010

Article features pelvic health problems, risk factors and treatment options for women

Pelvic health concerns in women are common -- yet how the issues impact sexuality and childbearing is not often discussed, according to Mayo Clinic Women's HealthSource.

12 Feb 2010

Big Ow awareness campaign

When it comes to symptoms of menopause like hot flashes, weight gain or trouble sleeping, chances are most women wouldn't hesitate to speak to their doctor. But there is another common - and equally distressing - effect of menopause that many women just keep to themselves. The Big Ow, also known as vaginal atrophy, will affect as many as two million Canadian women in the next 10 years - but most are too shy or embarrassed to talk about it, even with their doctor.

8 Feb 2010

New U.S. patent broadens Cytori Therapeutics' portfolio covering adipose-derived cell therapies

Cytori Therapeutics today received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the Company’s methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The ‘684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the ‘684 patent covers methods for delivering cell-enriched fat grafts to a patient’s breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body.

27 Jan 2010

Inadequate saliva and fluoride can contribute to tooth decay

Tooth enamel is tough, harder even than skeletal bone. But even with good dental hygiene, the enamel protecting teeth may show signs of decay in older adults. The January issue of Mayo Clinic Health Letter covers what to look out for and what to do to promote an enamel-friendly setting in the mouth. According to the newsletter, two significant contributors to tooth decay are too little saliva and inadequate fluoride.

18 Jan 2010

LinkMed’s portfolio company Likvor receives new order for Likvor CELDA

LinkMed’s portfolio company Likvor has received a new order for Likvor CELDA™ ,this time from Sahlgrenska University Hospital in Gothenburg. With Likvor CELDA™ the clinical will be able to dynamic measure the most important parameters concerning the patients’ cerebrospinal fluid including pressure and flow in a controlled and safe process.

9 Jan 2010

AUA updates clinical practice guideline on female stress urinary incontinence

A complete evaluation, including an assessment of post-void residual volume, is key when evaluating a female patient for surgery to treat stress urinary incontinence (SUI), according to a new clinical practice guideline released today by the American Urological Association (AUA).

8 Jan 2010

Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

WOCN Society launches campaign to raise awareness about benefits of specialized care

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Beaumont Hospital opens women's urology center

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

Adult female stress urinary incontinence: Uroplasty launches new endoscopic injection needle

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Likvor receives first order for Likvor CELDA system from Aalborg Hospital, North Denmark Region

Urinary catheterization of men and women: NAFC releases new consumer educational resource

Macroplastique effective for stress urinary incontinence in women

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Study: Several types of treatment can provide relief for pelvic floor disorders

Article features pelvic health problems, risk factors and treatment options for women

Big Ow awareness campaign

New U.S. patent broadens Cytori Therapeutics' portfolio covering adipose-derived cell therapies

Inadequate saliva and fluoride can contribute to tooth decay

LinkMed’s portfolio company Likvor receives new order for Likvor CELDA

AUA updates clinical practice guideline on female stress urinary incontinence

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in